Eloxx Pharmaceuticals, Inc. Stock price

Equities

ELOX

US29014R2022

Biotechnology & Medical Research

Delayed OTC Markets 11:59:45 2024-03-28 am EDT 5-day change 1st Jan Change
1 USD +11.11% Intraday chart for Eloxx Pharmaceuticals, Inc. +5.26% -16.67%
Sales 2023 * - Sales 2024 * - Capitalization 2.97M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.11 x
P/E ratio 2024 *
-0.12 x
Employees 18
Yield 2023 *
-
Yield 2024 *
-
Free-Float 95.63%
More Fundamentals * Assessed data
Dynamic Chart
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases CI
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment MT
Eloxx Pharmaceuticals, Inc. Enters into the Fifth Amendment to the Loan and Security Agreement CI
Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board CI
Eloxx Pharmaceuticals, Inc. and Zikani Therapeutics, Inc. Enter into the Fourth Amendment to the Loan and Security Agreement CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Oppenheimer Adjusts Eloxx Pharmaceuticals Price Target to $30 From $60, Maintains Outperform Rating MT
Eloxx Pharmaceuticals, Inc.(NasdaqCM:ELOX) dropped from S&P TMI Index CI
Eloxx Pharmaceuticals, Inc.(OTCPK:ELOX) dropped from NASDAQ Composite Index CI
Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development CI
Oppenheimer Raises Eloxx Pharmaceuticals Price Target to $60 From $55, Maintains Outperform Rating MT
Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013 CI
Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Top Premarket Gainers MT
More news

Latest transcript on Eloxx Pharmaceuticals, Inc.

1 day+11.11%
1 week+5.26%
Current month+16.41%
1 month+24.98%
3 months-21.26%
6 months-78.40%
Current year-16.67%
More quotes
1 week
0.85
Extreme 0.845
1.02
1 month
0.83
Extreme 0.83
1.39
Current year
0.67
Extreme 0.671
1.39
1 year
0.40
Extreme 0.4
10.90
3 years
0.40
Extreme 0.4
145.20
5 years
0.40
Extreme 0.4
538.40
10 years
0.40
Extreme 0.4
984.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-03-31
Director of Finance/CFO 67 20-10-31
Chief Tech/Sci/R&D Officer - 21-09-07
Members of the board TitleAgeSince
Director/Board Member 63 14-04-30
Director/Board Member 64 21-03-31
Chief Executive Officer - 21-03-31
More insiders
Date Price Change Volume
24-03-28 1 +11.11% 6 330
24-03-27 0.9 +5.88% 18,074
24-03-26 0.85 -5.56% 9,183
24-03-25 0.9 -1.21% 1,221
24-03-22 0.911 -4.11% 8,683

Delayed Quote OTC Markets, March 28, 2024 at 11:59 am EDT

More quotes
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9 USD
Average target price
30 USD
Spread / Average Target
+3,233.33%
Consensus
  1. Stock
  2. Equities
  3. Stock Eloxx Pharmaceuticals, Inc. - OTC Markets